Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Selective anticancer drugs

Nature Reviews Drug Discovery volume 1, pages 491–492 (2002)Cite this article

The success of Glivec (Gleevec in the United States) in the treatment of chronic myelogenous leukaemia (CML) has provided the proof of principle that cancer can be treated by identifying the underlying molecular defects and designing drugs to correct them. Promising results in trials with other molecularly targeted drugs, such as Iressa and Tarceva (Table 1), have given further encouragement for such approaches. And with genomics and proteomics technologies poised to have an increasing impact, it seems a new era in anticancer therapy is beginning.

Table 1 Other EGF/EGFR* drugs in the pipeline
Full size table

The bullet versus the sledgehammer

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Gross world revenues for selected anticancer drugs in the first quarter of 2002.
Figure 2: Incidence and mortality of selected cancers in the United States in 2002.

References

  1. Capdeville, R. et al. Glivec (STI571, imatinib), a rationally developed targeted anticancer drug. Nature Rev. Drug Discov. 1, 493–502 (2002).

    Article  CAS  Google Scholar 

  2. Ciardello, F. & Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958–2970 (2001).

    Google Scholar 

  3. Shawver, L. K., Slamon, D. & Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117–123 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. Jem, A. et al. Cancer statistics, 2002. CA Cancer J. Clin. 52, 23–47 (2002)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Managing Partners at AGW BioStrategy, 55 West 26 Street, Suite 10D, New York, 10010, New York, USA

    Joshua H. Atkins & Leland J. Gershell

Authors
  1. Joshua H. Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leland J. Gershell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leland J. Gershell.

Related links

Related links

DATABASES

Cancer.gov

chronic myelogenous leukaemia

colorectal cancer

non-small-cell-lung cancer

oesophageal cancer

pancreatic cancer

prostate cancer

renal-cell cancer

LocusLink

ABL

BCR

EGFR

HER2

HER4

c-KIT

PKC

PDGFR

Medscape DrugInfo

cisplatin

cyclophosphamide

doxorubicin

etoposide

5-fluorouracil

flutamide

Glivec

Herceptin

methotrexate

tamoxifen

Taxol

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atkins, J., Gershell, L. Selective anticancer drugs. Nat Rev Drug Discov 1, 491–492 (2002). https://doi.org/10.1038/nrd842

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd842

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing